NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Veri Medtech Holdings, Inc. (OTC Markets: (“VRHI”) ("Veri Medtech") announced today that it has retained Salberg & Company, P.A., as its PCAOB auditor, in furtherance of the uplisting process. For more information, please visit: http://www.salbergco.com. "Veri Medtech (VRHI) continues to execute on its mission to be the premier provider of healthcare technology services and products worldwide. Retaining Salberg & Company is an important strategic next step in the ...

Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease , is pleased to announce receipt of notification that the patent "Xanthine Oxidase Inhibitor Formulations" will be granted by the European Patent Of ...

WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and present ...

Company Participation in Investor Events - IDEAYA Biosciences, Inc. will participate in investor relations events including a fireside chat on May 8, 2025, and another on May 20, 2025 [1] - The events will feature Yujiro S. Hata, President and CEO, and will be hosted by notable analysts from Barclays and RBC Capital Markets [1] Company Overview - IDEAYA is a precision medicine oncology company focused on discovering and developing targeted therapeutics using molecular diagnostics [2] - The company integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its therapies [2] - IDEAYA is particularly focused on synthetic lethality, an emerging class of precision medicine targets [2]

Core Insights - The field of psychedelic medicine is emerging, attracting investor interest due to its potential for growth and innovation [1] - Compass Pathways experienced a 13% increase in share price following the announcement of a completed step in its clinical trial [1] Company Developments - Compass Pathways has completed dosing in a late-stage clinical trial for its psilocybin treatment, COMP005 [2] - The phase 3 trial involves 258 patients with moderate to severe depression who have not responded to at least two prior treatments, with dosing conducted at 32 sites in the U.S. [3][4] - The company is expected to publish six-week primary endpoint results by the end of June [3] Industry Context - The CEO of Compass Pathways emphasized the milestone as critical in addressing the unmet need in treatment-resistant depression, highlighting the legitimacy of psychedelics as potential therapies for serious psychological disorders [5]

Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimbursement for their PancraGEN® test. The Centers for Medicare & Medicaid Services (CMS ...

Core Viewpoint - Shineco, Inc. has announced the acquisition of a 51% equity interest in InfiniClone Limited, a biotechnology company specializing in regenerative medicine, marking a significant step into the stem cell technology sector [2][3][6]. Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to improve quality of life through safe and efficient health solutions [7]. - The company has developed 33 types of in vitro diagnostic reagents and related medical devices, alongside producing and selling healthy foods [7]. Acquisition Details - The acquisition involves a payment of $19,895,600 in cash and the issuance of 3,450,000 shares of common stock to the seller, Dr. Lim Kah Meng [3]. - InfiniClone holds 29 global patents, including five invention patents, which cover major markets such as the US, Europe, and Asia, providing a competitive edge in stem cell technology [4]. InfiniClone's Technology - InfiniClone's core technologies include cell reprogramming, stem cell culture using microcarrier technology, and the management of induced pluripotent stem cell (iPSC) libraries, which can enhance cell expansion throughput by three to ten times compared to existing methods [4]. - The technology is expected to reduce production costs per cell by over 60% and significantly shorten the time required for clinical applications, such as treating Parkinson's and Alzheimer's diseases [4]. Leadership and Expertise - Dr. Lim Kah Meng, the founder of InfiniClone, has over 20 years of experience in molecular research related to stem cell and regenerative medicine, and has founded several biotechnology companies [5]. - Shineco's CEO, Jennifer Zhan, emphasized the acquisition as a key milestone for entering the regenerative medicine field and highlighted the potential for transforming InfiniClone's technology from laboratory to clinical applications [6].

Core Insights - Mesoblast has expanded coverage for its product Ryoncil® (remestemcel-L) to 104 million insured lives in the U.S. through government and commercial payers [1][2] - Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older [4] Coverage Expansion - 37 out of 51 states provide fee-for-service Medicaid coverage for Ryoncil®, covering 20 million lives, which is 80% of total Medicaid fee-for-service lives [2] - Mandatory coverage for an additional 24 million lives will begin on July 1, 2025 [2] - Commercial plans cover 84 million lives, excluding medical exceptions policies, indicating that the actual commercial coverage is likely higher [2] Company Overview - Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing a proprietary mesenchymal lineage cell therapy technology platform [3] - The company is also developing additional therapies for other inflammatory diseases and conditions such as heart failure and chronic low back pain [5] Intellectual Property - Mesoblast holds a strong global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection expected to last until at least 2041 in major markets [6] Manufacturing Capabilities - The company has proprietary manufacturing processes that yield industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring availability to patients worldwide [7]

Core Insights - Tevogen Bio Holdings Inc. has commissioned Databricks, Inc. to enhance the development of its AI-driven target prediction model, PredicTcell, aimed at precision immunotherapy [1][2] - The collaboration will focus on modeling immunologically active HLA+ peptide complexes and predicting T cell receptor (TCR) engagement, utilizing the ExacTcell™ platform [2] - This initiative represents a significant step in Tevogen's AI strategy, which is designed to transform precision medicine [3] Company Overview - Tevogen is dedicated to providing innovative and affordable healthcare solutions, operating through three strategic pillars: Tevogen Bio, Tevogen.AI, and Tevogen Generics [3] - Tevogen Bio focuses on genetically unmodified precision T cell therapies, while Tevogen.AI leverages AI for drug discovery and healthcare optimization [3] - The company possesses all key intellectual property and is led by a team with extensive experience in drug development and global product launches [3] Strategic Partnerships - Databricks will supply a dedicated data engineering team and expertise in data and AI systems to support the development of PredicTcell [2][6] - Microsoft Research is also contributing digital infrastructure and AI expertise to bolster the initiative [6]

Shares of Verve Therapeutics (VERV) surged 26.4% on Monday and continue to soar today after the company announced positive initial data from an early-stage study of its investigational candidate, VERVE-102, which is being developed for reducing cholesterol levels. VERVE-102 is a novel, in vivo, investigational base editing medicine.The patient population enrolled in the phase Ib Heart-2 study comprises individuals with heterozygous familial hypercholesterolemia and/or premature coronary artery disease — two ...